The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy: Results from the MD Anderson INTERCEPT Program.
 
Andrew Jared Pellatt
No Relationships to Disclose
 
Alisha Heather Bent
No Relationships to Disclose
 
Christine Megerdichian Parseghian
No Relationships to Disclose
 
Benny Johnson
Consulting or Advisory Role - Gritstone Bio; Incyte; Insmed; Iota Biosciences; Pfizer; Taiho Oncology
Research Funding - Bristol-Myers Squibb (Inst); Gateway Foundation (Inst); Syntrix Biosystems (Inst)
 
Ryan W Huey
Honoraria - Aptitude Health; Clinical Care Targeted Communications LLC
Travel, Accommodations, Expenses - Clinical Care Targeted Communications LLC
 
Kanwal Pratap Singh Raghav
Honoraria - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Consulting or Advisory Role - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Research Funding - Abbvie (Inst); Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Guardant Health (Inst); HiberCell (Inst); Innovent Biologics (Inst); Janssen (Inst); Merck Serono (Inst); Roche/Genentech (Inst); UCB (Inst); Xencor (Inst)
 
Van K. Morris
Consulting or Advisory Role - Incyte; Regeneron
Research Funding - Bicara Therapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Novartis (Inst); Pfizer (Inst)
 
Michael J. Overman
Consulting or Advisory Role - 3D Medicines; Array BioPharma; Bristol-Myers Squibb; Eisai; Gritstone Bio; Janssen; Janssen; MedImmune; Merck; Novartis; Pfizer; Pfizer; Promega; Roche/Genentech; Spectrum Pharmaceuticals
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
Maria Pia Morelli
No Relationships to Disclose
 
Jason Willis
Honoraria - Bayer; Cor2Ed
 
Phat Le
No Relationships to Disclose
 
John Paul Y.C. Shen
Stock and Other Ownership Interests - Agios; Syndax; Syndax
Consulting or Advisory Role - Engine Biosciences
Research Funding - BostonGene; Celsius Therapeutics; Celsius Therapeutics
 
Michael Sangmin Lee
Consulting or Advisory Role - Bayer Health; Delcath Systems; G1 Therapeutics; Imvax; Pfizer
Research Funding - Arcus Biosciences (Inst); Boehringer Ingelheim (Inst); EpimAb BioTherapeutics (Inst); Erasca, Inc (Inst); Merck (Inst); Repare Therapeutics (Inst); TriSalus Life Sciences (Inst); Xilis (Inst)
 
Kristin Alfaro
Consulting or Advisory Role - Abbvie; SDP Oncology
 
Kathryn Aziz
Employment - MD Anderson Cancer Center
 
Robert J. Kell
Employment - MD Anderson Cancer Center; MD Anderson Cancer Center (I)
 
Ryan Sun
Consulting or Advisory Role - Boehringer Ingelheim; Boehringer Ingelheim
Research Funding - Sanofi
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Iylon; Lutris; Navire; Xilis
Consulting or Advisory Role - Abbvie; Accademia Nazionale Di Medicina (ACCMED); Amal Therapeutics; Amgen; AstraZeneca/MedImmune; AVEO; Bayer Health; Bicara Therapeutics; Black Diamond Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Cardiff Oncology; Carina Biotech; CureTeq; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Foundation Medicine; Frontier Medicines; Genentech; Genomic Health; Gilead Sciences; GlaxoSmithKline; HalioDx; Harbinger Oncology, Inc; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Lutris; Merck; Mirati Therapeutics; NeoGenomics Laboratories; Novartis; Numab; Ono Pharmaceutical; Pfizer; Redx Pharma; Repare Therapeutics; Replimune; Roche; Sanofi; Servier; Tachyon Therapeutics; Taiho Pharmaceutical; Takeda; Tempus; Xilis; Zentalis
Research Funding - Amgen; Array BioPharma; Biocartis; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; MedImmune; Novartis; Sanofi
 
Arvind Dasari
Consulting or Advisory Role - HutcMed; Illumina/GRAIL; Personalis; SIRTIS; Takeda
Research Funding - Eisai (Inst); Guardant Health (Inst); Hutchison MediPharma (Inst); Merck (Inst); Natera (Inst); XENCOR (Inst)
Travel, Accommodations, Expenses - Hutchison MediPharma; Takeda